Any suggestion of a CR would be delusional for the company at this time.
They have effectively ended the costs of clinical trials and technical work for "partners" is, we are told, is revenue.
The company has expensive executives who seem to have achieved very little, if Starpharma is short of cash the solution is obvious, make the rewards revenue driven!
Ann: Investor Webinar Notification - SPL Business Update, page-23
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
